Immune-suppressive properties of the tumor microenvironment

Effect of NKG2D ligand expression on host immune responses

(2015) Marine Champsaur et al.   IMMUNOLOGICAL REVIEWS

Cutting Edge: The Metalloproteinase ADAM17/TNF- -Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein

(2014) P. Boutet et al.   JOURNAL OF IMMUNOLOGY

Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway

(2014) H. Shime et al.   JOURNAL OF IMMUNOLOGY

Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)

(2013) Theresa L. Whiteside   BIOCHEMICAL SOCIETY TRANSACTIONS

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

The expression, function, and clinical relevance of B7 family members in cancer

(2012) Barbara Seliger et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase

(2012) Mads Hald Andersen   CANCER IMMUNOLOGY IMMUNOTHERAPY

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

(2012) Vafa Shahabi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion

(2012) M. Platten et al.   CANCER RESEARCH

Cellular Constituents of Immune Escape within the Tumor Microenvironment

(2012) S. P. Kerkar et al.   CANCER RESEARCH

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Immunoregulatory molecules are master regulators of inflammation during the immune response

(2012) Hortensia de la Fuente et al.   FEBS LETTERS

Tryptophan hydroxylase-1 regulates immune tolerance and inflammation

(2012) Elizabeth C. Nowak et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release

(2012) P. Jayaraman et al.   JOURNAL OF IMMUNOLOGY

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

(2012) L. Pilotte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

(2012) S. A. Rosenberg   Science Translational Medicine

Recent advances on the role of tumor exosomes in immunosuppression and disease progression

(2012) Paola Filipazzi et al.   SEMINARS IN CANCER BIOLOGY

CD73: a potent suppressor of antitumor immune responses

(2012) Paul. A. Beavis et al.   TRENDS IN IMMUNOLOGY

Endogenous modulators of inflammatory cell recruitment

(2012) George Hajishengallis et al.   TRENDS IN IMMUNOLOGY

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape

(2012) Salem Chouaib et al.   Frontiers in Immunology

The role of the EP receptors for prostaglandin E2 in skin and skin cancer

(2011) J. E. Rundhaug et al.   CANCER AND METASTASIS REVIEWS

Matrix Metalloproteinase-2 Conditions Human Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12- and OX40L-Dependent Pathway

(2011) Emmanuelle Godefroy et al.   CANCER CELL

Suppression of T-cell responses by tumor metabolites

(2011) Katrin Singer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

(2011) Adam T. Waickman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity

(2011) Sebastian F. M. Häusler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2

(2011) S. Textor et al.   CANCER RESEARCH

Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide

(2011) I. B. Barsoum et al.   CANCER RESEARCH

Lactate: A Metabolic Key Player in Cancer

(2011) F. Hirschhaeuser et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

Ipilimumab

(2011) Fiona Cameron et al.   DRUGS

IL-17 + Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer

(2011) Ilona Kryczek et al.   JOURNAL OF IMMUNOLOGY

Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells

(2011) S. Ryzhov et al.   JOURNAL OF IMMUNOLOGY

Nitric oxide and redox mechanisms in the immune response

(2011) David A. Wink et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Beyond Ipilimumab: New Approaches Target the Immunological Synapse

(2011) K. Garber   JNCI-Journal of the National Cancer Institute

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells

(2011) A. C. Benitez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments

(2011) Douglas D. Taylor et al.   Seminars in Immunopathology

ADAM17: a molecular switch to control inflammation and tissue regeneration

(2011) Jürgen Scheller et al.   TRENDS IN IMMUNOLOGY

Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes

(2010) Yunyun Su et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Tumors as Organs: Complex Tissues that Interface with the Entire Organism

(2010) Mikala Egeblad et al.   DEVELOPMENTAL CELL

Hallmarks of cancer: Interactions with the tumor stroma

(2010) Kristian Pietras et al.   EXPERIMENTAL CELL RESEARCH

Adenosine and Prostaglandin E2Cooperate in the Suppression of Immune Responses Mediated by Adaptive Regulatory T Cells

(2010) Magis Mandapathil et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Extracellular adenosine triphosphate and adenosine in cancer

(2010) J Stagg et al.   ONCOGENE

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

(2010) Margaret K. Callahan et al.   SEMINARS IN ONCOLOGY

The Yin-Yang of Tumor-Associated Neutrophils

(2009) Alberto Mantovani   CANCER CELL

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

(2009) F. Colotta et al.   CARCINOGENESIS

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

(2009) A. Paschen et al.   CLINICAL CANCER RESEARCH

Fine tuning the immune response through B7-H3 and B7-H4

(2009) Kyung H. Yi et al.   IMMUNOLOGICAL REVIEWS

Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide

(2008) D. R. Siemens et al.   CANCER RESEARCH

Tumor-Associated MICA Is Shed by ADAM Proteases

(2008) I. Waldhauer et al.   CANCER RESEARCH

Induction of myeloid-derived suppressor cells by tumor exosomes

(2008) Xiaoyu Xiang et al.   INTERNATIONAL JOURNAL OF CANCER

Suppressive Influences in the Immune Response to Cancer

(2008) Vincenzo Bronte et al.   JOURNAL OF IMMUNOTHERAPY

More insights into the immunosuppressive potential of tumor exosomes

(2008) Veronica Huber et al.   Journal of Translational Medicine

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

(2008) György Haskó et al.   NATURE REVIEWS DRUG DISCOVERY

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer

(2008) Jessica Pruessmeyer et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY